Antonio Lauletta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antonio Lauletta has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Matteo Garibaldi
8 shared publications- Matteo Garibaldi
Department of Neuroscience, Mental Health and Sensory Organs (NESMOS) Sapienza University of Rome, Sant'Andrea Hospital Rome Italy
6 shared publications - Laura Fionda
Neuromuscular and Rare Disease Centre, Neurology Unit, Sant’Andrea Hospital, Rome, Italy
5 shared publications - Luca Leonardi
Neuromuscular and Rare Disease Centre, Neurology Unit Sant'Andrea Hospital Rome Italy
5 shared publications - Francesca Forcina
Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Rome, Italy
4 shared publications - Laura Tufano
Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Rome, Italy
4 shared publications
Latest Publications
- 12 August 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 67
294th ENMC international workshop: Diagnosis and management of paraproteinemic myopathies focusing on sporadic late-onset nemaline myopathy (SLONM) and light-chain (AL) amyloid myopathy. 27th -29th March 2026, Hoofddorp, The Netherlands
- 12 August 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 67
294th ENMC international workshop: Diagnosis and management of paraproteinemic myopathies focusing on sporadic late-onset nemaline myopathy (SLONM) and light-chain (AL) amyloid myopathy. 27th -29th March 2026, Hoofddorp, The Netherlands
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e218081
Comparative Study of Sporadic and Immune Checkpoint Inhibitor–Related Forms of Myasthenia Gravis-Myositis Overlap Syndrome
Background and ObjectivesMyasthenia gravis-inflammatory myopathy (MG-IM) overlap syndrome can occur as an immune-related adverse event (irAE) after immune checkpoint inhibitor (ICI) therapy. Before...
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e218081
Comparative Study of Sporadic and Immune Checkpoint Inhibitor–Related Forms of Myasthenia Gravis-Myositis Overlap Syndrome
Background and ObjectivesMyasthenia gravis-inflammatory myopathy (MG-IM) overlap syndrome can occur as an immune-related adverse event (irAE) after immune checkpoint inhibitor (ICI) therapy. Before...
- Open Access
- 27 April 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (1) , 131-138
Muscle Ultrasound in Inclusion Body Myositis: Integrating Qualitative and Quantitative Approaches With Clinical and MRI Findings
Introduction/Aims: Inclusion body myositis (IBM) is an inflammatory myopathy with an insidious onset, often making diagnosis challenging. Although neuroimaging has recently been included in diagnostic criteria, the role of muscle ultrasound—despite being a rapid and cost‐effective tool—in IBM has been less extensively characterized. In this study, we aimed to explore whether qualitative and quantitative muscle ultrasound measures reflect the pattern of muscle involvement in IBM and are associated with magnetic resonance imaging (MRI) findings. Methods: Thirteen patients with histologically confirmed IBM underwent clinical evaluation, including the IBM Functional Rating Scale (IBM‐FRS) and Medical Research Council (MRC) grading. Qualitative (Heckmatt scale, from 1 to 4) and quantitative (muscle echo‐intensity and thickness z‐scores) ultrasound assessments were performed on fourteen muscles bilaterally. Lower limb muscle MRI was conducted using T1‐weighted (with Mercuri score) and STIR sequences. Correlations between ultrasound parameters and MRI findings were analyzed. Results: Qualitative ultrasound assessment showed increased echogenicity, mainly in flexor digitorum profundus, vastus lateralis, rectus femoris, tibialis anterior, and medial gastrocnemius. Quantitative analysis confirmed elevated echo‐intensity in these muscles, with milder involvement of tibialis anterior and lateral gastrocnemius. Both qualitative Heckmatt scores and quantitative muscle echo‐intensity scores showed positive associations with MRI T1 Mercuri scores ( p < 0.001). Discussion: In this study, both qualitative and quantitative muscle ultrasound reflected the characteristic pattern of muscle involvement in IBM and showed associations with MRI findings, supporting their utility in describing the pattern and extent of muscle damage.
- 27 April 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (1) , 131-138
Open AccessMuscle Ultrasound in Inclusion Body Myositis: Integrating Qualitative and Quantitative Approaches With Clinical and MRI Findings
Introduction/Aims: Inclusion body myositis (IBM) is an inflammatory myopathy with an insidious onset, often making diagnosis challenging. Although neuroimaging has recently been included in diagnostic criteria, the role of muscle ultrasound—despite being a rapid and cost‐effective tool—in IBM has been less extensively characterized. In this study, we aimed to explore whether qualitative and quantitative muscle ultrasound measures reflect the pattern of muscle involvement in IBM and are associated with magnetic resonance imaging (MRI) findings. Methods: Thirteen patients with histologically confirmed IBM underwent clinical evaluation, including the IBM Functional Rating Scale (IBM‐FRS) and Medical Research Council (MRC) grading. Qualitative (Heckmatt scale, from 1 to 4) and quantitative (muscle echo‐intensity and thickness z‐scores) ultrasound assessments were performed on fourteen muscles bilaterally. Lower limb muscle MRI was conducted using T1‐weighted (with Mercuri score) and STIR sequences. Correlations between ultrasound parameters and MRI findings were analyzed. Results: Qualitative ultrasound assessment showed increased echogenicity, mainly in flexor digitorum profundus, vastus lateralis, rectus femoris, tibialis anterior, and medial gastrocnemius. Quantitative analysis confirmed elevated echo‐intensity in these muscles, with milder involvement of tibialis anterior and lateral gastrocnemius. Both qualitative Heckmatt scores and quantitative muscle echo‐intensity scores showed positive associations with MRI T1 Mercuri scores ( p < 0.001). Discussion: In this study, both qualitative and quantitative muscle ultrasound reflected the characteristic pattern of muscle involvement in IBM and showed associations with MRI findings, supporting their utility in describing the pattern and extent of muscle damage.
- Open Access
- 20 November 2025
- Published by Elsevier in Autoimmunity Reviews
- Vol. 25 (2) , 103960
Sporadic late-onset nemaline myopathy (SLONM): Data from a case series and literature review of 144 patients
- 20 November 2025
- Published by Elsevier in Autoimmunity Reviews
- Vol. 25 (2) , 103960
Open AccessSporadic late-onset nemaline myopathy (SLONM): Data from a case series and literature review of 144 patients
- 22 July 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 257, 109069
Response to letter to the editor: “Emergent role of complement inhibitors in myasthenic crisis” (CNN-D-25-2224)
- 22 July 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 257, 109069
Response to letter to the editor: “Emergent role of complement inhibitors in myasthenic crisis” (CNN-D-25-2224)
- Open Access
- 12 July 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (8) , 1-3
Correction: Refining the clinical and therapeutic spectrum of granulomatous myositis from a large cohort of patients
- 12 July 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (8) , 1-3
Open AccessCorrection: Refining the clinical and therapeutic spectrum of granulomatous myositis from a large cohort of patients
- 26 June 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (7) , 1-12
Mitochondrial pathology in inflammatory myopathies: a marker of worse clinical outcome
Objectives Mitochondrial dysfunction is well documented in inclusion body myositis (IBM), but its role in non-IBM myositis remains unclear. This study aimed to investigate the prevalence and clinical significance of mitochondrial pathology in non-IBM myositis and to assess its potential role as a marker for disease progression towards IBM, treatment response, and clinical outcomes. Methods Muscle biopsies from 850 patients with inflammatory myopathy (IM) across 6 neuromuscular centers in Italy, France, and Germany were retrospectively analyzed. Inclusion required meeting diagnostic criteria for definite adult IM, mitochondrial pathology (age-exceeding numbers of COX-negative fibers), and exclusion of definite IBM according to Hilton-Jones 2013 criteria. The percentage of COX-negative fibers was quantified, correlated with clinical outcomes, and compared with myositis control cases without relevant signs of mitochondrial alterations. Results Twenty-five patients with non-IBM myositis and mitochondrial abnormalities were identified. These patients, predominantly women (68%), had a mean onset age of 58.8 years. Polymyositis with mitochondrial pathology (PM-Mito) and nonspecific myositis (NSM) were the most prevalent subtypes (72%). The mean percentage of COX-negative fibers was 3% (0.25–8.5%) in these patients. The presence of mitochondrial pathology was associated with treatment refractoriness and worse clinical outcome evaluated based on residual muscle weakness and the level of independence (p < 0.005). A higher percentage of COX-negative fibers also correlated with poorer clinical outcomes (p = 0.031). Four patients, initially diagnosed with PM-Mito and NSM, progressed to definite IBM. Conclusions Mitochondrial dysfunction represents a key element informing about disease severity and poor clinical outcomes in non-IBM myositis. It may predict progression to IBM, especially in PM-Mito and NSM, and guide treatment strategies.
- 26 June 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (7) , 1-12
Mitochondrial pathology in inflammatory myopathies: a marker of worse clinical outcome
Objectives Mitochondrial dysfunction is well documented in inclusion body myositis (IBM), but its role in non-IBM myositis remains unclear. This study aimed to investigate the prevalence and clinical significance of mitochondrial pathology in non-IBM myositis and to assess its potential role as a marker for disease progression towards IBM, treatment response, and clinical outcomes. Methods Muscle biopsies from 850 patients with inflammatory myopathy (IM) across 6 neuromuscular centers in Italy, France, and Germany were retrospectively analyzed. Inclusion required meeting diagnostic criteria for definite adult IM, mitochondrial pathology (age-exceeding numbers of COX-negative fibers), and exclusion of definite IBM according to Hilton-Jones 2013 criteria. The percentage of COX-negative fibers was quantified, correlated with clinical outcomes, and compared with myositis control cases without relevant signs of mitochondrial alterations. Results Twenty-five patients with non-IBM myositis and mitochondrial abnormalities were identified. These patients, predominantly women (68%), had a mean onset age of 58.8 years. Polymyositis with mitochondrial pathology (PM-Mito) and nonspecific myositis (NSM) were the most prevalent subtypes (72%). The mean percentage of COX-negative fibers was 3% (0.25–8.5%) in these patients. The presence of mitochondrial pathology was associated with treatment refractoriness and worse clinical outcome evaluated based on residual muscle weakness and the level of independence (p < 0.005). A higher percentage of COX-negative fibers also correlated with poorer clinical outcomes (p = 0.031). Four patients, initially diagnosed with PM-Mito and NSM, progressed to definite IBM. Conclusions Mitochondrial dysfunction represents a key element informing about disease severity and poor clinical outcomes in non-IBM myositis. It may predict progression to IBM, especially in PM-Mito and NSM, and guide treatment strategies.
- Open Access
- 9 June 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 256, 109011
Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how
- 9 June 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 256, 109011
Open AccessEmergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how
- Open Access
- 21 January 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 470, 123400
High prevalence of facioscapulohumeral muscular dystrophy (FSHD) and inflammatory myopathies association: Is there an interplay?
- 21 January 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 470, 123400
Open AccessHigh prevalence of facioscapulohumeral muscular dystrophy (FSHD) and inflammatory myopathies association: Is there an interplay?